Clinical trial
CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders
NCT00579137 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders
- Lead sponsor
- Baylor College of Medicine
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- October 31, 2007
- Completion date
- October 31, 2009
- Enrollment
- 3 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
severe combined immunodeficiency disease, severe primary immunodeficiency disorder, undefined t cell deficiency disorder, wiskott-aldrick syndrome